Login to Your Account



Other News To Note


Tuesday, August 30, 2011
NovAliX SAS, of Strasbourg, France, signed a drug discovery collaboration with Galapagos NV, of Mechelen, Belgium, in the field of osteoarthritis. Under the terms, NovAliX will handle the discovery of specific small-molecule lead candidates for a target chosen by Galapagos and then will identify hits using its Graffinity fragment-based screening technology. In exchange, NovAliX will receive technology access fees, research funding and potential milestones. Specific financial terms were not disclosed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription